• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血酶诱导人血小板中新型33 kDa丝氨酸/苏氨酸激酶的激活。

Thrombin-induced activation of the novel 33-kDa serine/threonine kinase in human platelets.

作者信息

Ido M, Ogawa H, Kato S, Hayashi K, Suzuki K

机构信息

Department of Molecular Pathobiology, Mie University School of Medicine, Japan.

出版信息

Pol J Pharmacol. 1996 Jan-Feb;48(1):105-7.

PMID:9112637
Abstract

In order to examine a possible role of protein kinases in the signal transduction of platelet activation, thrombin-stimulated human platelets were analyzed for protein kinase activity with a denaturation/renaturation method. Treatment of platelets with thrombin resulted in a rapid activation of a 33-kDa protein kinase (PK33) using casein as an in vitro substrate. The concentration of thrombin to activate PK33 was proportional to that required to induce platelet aggregation. PK33 was also activated by a thrombin receptor agonist peptide, but not by hirudin-treated or diisopropylphosphate-inactivated thrombin. Phosphoamino acid analysis showed that PK33 is a serine/threonine kinase. Comparative analysis using specific substrate and inhibitors revealed that PK33 is distinct from casein kinase I, casein kinase II, P34cdc2, and mitogen activated protein kinase. These findings suggest that platelet activation mediated by thrombin receptor requires PK33 activation.

摘要

为了研究蛋白激酶在血小板激活信号转导中的可能作用,采用变性/复性方法分析了凝血酶刺激的人血小板的蛋白激酶活性。用酪蛋白作为体外底物,凝血酶处理血小板可导致一种33 kDa蛋白激酶(PK33)迅速激活。激活PK33的凝血酶浓度与诱导血小板聚集所需的浓度成正比。凝血酶受体激动肽也可激活PK33,但水蛭素处理的或二异丙基磷酸酯灭活的凝血酶则不能激活PK33。磷酸氨基酸分析表明PK33是一种丝氨酸/苏氨酸激酶。使用特异性底物和抑制剂的比较分析显示,PK33不同于酪蛋白激酶I、酪蛋白激酶II、P34cdc2和丝裂原活化蛋白激酶。这些发现提示,凝血酶受体介导的血小板激活需要PK33的激活。

相似文献

1
Thrombin-induced activation of the novel 33-kDa serine/threonine kinase in human platelets.凝血酶诱导人血小板中新型33 kDa丝氨酸/苏氨酸激酶的激活。
Pol J Pharmacol. 1996 Jan-Feb;48(1):105-7.
2
The thrombin receptor transmits signals through a 33-kDa protein kinase in human platelets.凝血酶受体通过人血小板中的一种33 kDa蛋白激酶传递信号。
Biochem Biophys Res Commun. 1994 Sep 15;203(2):907-13. doi: 10.1006/bbrc.1994.2268.
3
Ca(2+)-dependent activation of the 33-kDa protein kinase transmits thrombin receptor signals in human platelets.
Thromb Haemost. 1996 Sep;76(3):439-43.
4
Identification of a novel 33-kDa Ser/Thr kinase that phosphorylates the cytoplasmic tail of protease-activated receptor 1 (thrombin receptor) in human platelets.一种新型33 kDa丝氨酸/苏氨酸激酶的鉴定,该激酶可磷酸化人血小板中蛋白酶激活受体1(凝血酶受体)的胞质尾。
Thromb Haemost. 2000 Apr;83(4):617-21.
5
Secreted ADP plays a central role in thrombin-induced phospholipase D activation in human platelets.分泌型ADP在凝血酶诱导的人血小板磷脂酶D激活过程中起核心作用。
Thromb Haemost. 1998 Dec;80(6):976-81.
6
Amyloid beta peptide-activated signal pathways in human platelets.人血小板中β-淀粉样肽激活的信号通路。
Eur J Pharmacol. 2008 Jul 7;588(2-3):259-66. doi: 10.1016/j.ejphar.2008.04.040. Epub 2008 Apr 22.
7
Cytoskeletal changes in platelets induced by thrombin and phorbol myristate acetate (PMA).凝血酶和佛波酯(PMA)诱导的血小板细胞骨架变化
Cell Biol Int. 1998;22(6):429-35. doi: 10.1006/cbir.1998.0271.
8
p42 mitogen-activated protein kinase and p90 ribosomal S6 kinase are selectively phosphorylated and activated during thrombin-induced platelet activation and aggregation.在凝血酶诱导的血小板活化和聚集过程中,p42丝裂原活化蛋白激酶和p90核糖体S6激酶被选择性磷酸化并激活。
Mol Cell Biol. 1994 Jan;14(1):463-72. doi: 10.1128/mcb.14.1.463-472.1994.
9
Effect of neutrophil adhesion on the size of aggregates formed by agonist-activated platelets.中性粒细胞黏附对激动剂激活的血小板形成聚集体大小的影响。
Platelets. 2005 Dec;16(8):482-91. doi: 10.1080/09537100500215455.
10
Independent activation of endogenous p21-activated protein kinase-3 (PAK3) and JNK by thrombin in CCL39 fibroblasts.凝血酶在CCL39成纤维细胞中对内源性p21激活蛋白激酶3(PAK3)和JNK的独立激活作用。
J Cell Physiol. 2000 Nov;185(2):235-43. doi: 10.1002/1097-4652(200011)185:2<235::AID-JCP8>3.0.CO;2-D.